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patients with no episodes (HR 7.5; 95% CI 2.6, 22.0; p  0.01). CONCLUSIONS: 
Upper GI symptoms were signiﬁcantly associated with poor adherence to and discon-
tinuation of low-dose ASA. Strategies to help patients continue with low-dose ASA 
cardioprotection are warranted.
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WITH AN A2RA OR AN ACE ANTIHYPERTENSIVE IN AUSTRALIA
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OBJECTIVES: To assess persistence to the combinations of dihydropyridine (DHP) 
calcium channel blockers (CCB) with an Angiotension Converting Enzyme (ACE) 
inhibitors or an Angiotension II Receptor Antagonist (A2RA), using PBS claims data 
provided by Medicare Australia. METHODS: This analysis is based on all scripts 
supplied to a one in ten sample of the Australian population drawn from de-identiﬁed 
Pharmaceutical Beneﬁts payment records from January 2003 to December 2006. Ini-
tiation occurred with 2 consecutive months of an A2RA or an ACE combined with a 
DHP following at least 6 months without a DHP combination. Treatment cessation 
was 3 consecutive months of none or just one of the drugs making up the combination. 
Hazard ratios (HR) were derived and adjusted for patient age/ sex and initiating 
 speciality. RESULTS: More than 17,500 Concessional patients, initiated on a DHP 
combined with an A2RA and more than 12,000 Concessional patients, initiated on a 
DHP combined with an ACE, had their persistence to the combination assessed. 
Median persistence [95% CI] differed between DHP combinations: Lercanidipine/
A2RA 23 months [22–25], Felodipine/A2RA 20 months [18–22], Nifedipine/A2RA 
17 months [16–18], and Amlodipine/A2RA 14 months [13–15]. Using Lercanidipine/
A2RA as the reference (HR  1.00), patients were signiﬁcantly more likely to cease 
the other combinations Felodipine/A2RA (8.7%), Nifedipine/A2RA (18.5%) and 
Amlodipine/A2RA (33.9%). Lercanidipine/ACE 24 months [22–26], felodipine/ACE 
21 months [19–24], nifedipine/ACE 16 months [14–18], and amlodipine/ACE 15 
months [14–17]. Using Lercanidipine/ACE as the reference (HR  1.00), patients were 
more likely to cease the other combinations felodipine/ACE (7.2%), nifedipine/ACE 
(26.5%) and amlodipine/ACE (28.6%). CONCLUSIONS: In terms of optimal treat-
ment persistence, lercanidipine seems to be the best DHP to combine with an A2RA 
or an ACE, while amlodipine seems to be the worst DHP to combine with an A2RA 
or an ACE.
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INFLUENCING FACTORS TO A GOOD ADHERENCE IN PATIENTS WITH 
CHRONIC HEART DISEASES
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OBJECTIVES: To identify enhancing factors of the medication adherence using the 
data from a randomized trial of patients with chronic heart diseases. METHODS: We 
used the data from a randomized trial involving a total of 6967 patients with chronic 
heart diseases. This trial followed up them with an average of 5 years. Adherence rate 
was obtained by the division of a number of days to take a targeted medicine by 365 
days each year for each patient. The targeted medicine was the one assigned by ran-
domization. An overall adherence rate for each patient was deﬁned by an average of 
annual adherence rates during the follow-up period. Good medication adherence was 
deﬁned by the overall adherence rate of 80% or more. An adjusted odds ratio (OR) 
was used to show the degree of inﬂuence to a good adherence. RESULTS: Very high 
rate (94%) of good adherence was observed since the medication was an assigned 
drug in a randomized trial. Enhancing the odds of good adherence was women (OR 
 1.13, P  0.007), age (OR per 5-year increase  2.33, P  0.17), patients taking 5 
or more medicines (OR  1.45, P  0.001), and good status on diet therapy (OR  
1.95, P  0.001). Conversely, smokers decreased the adherence by 12% (P  0.008) 
and patients with previous stroke decreased the adherence by 29% (P  0.001). 
CONCLUSIONS: Patients taking many drugs or receiving diet therapy and women 
showed a statistically signiﬁcant increase in the medication adherence.
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OBJECTIVES: The aim of this study was to estimate predictors of non-persistence 
with different statin treatments by the analysis of a general practitioner’s (GP’s) data-
base covered a population of 144,000 inhabitants. METHODS: We analysed a cohort 
of adult patients (35 years) who newly initiated statin therapy between January 
1,2005 and December 31,2005. The initiator status was conﬁrmed by the absence of 
any statin prescription within 365 days prior to statin initiation. Persistence of statin 
utilization was analysed over 3 years follow-up period. The period covered by a pre-
scription was deﬁned by the number of tablets dispensed, based on one tablets per 
day. Treatment was considered discontinued if the interval between two prescriptions 
exceeded number of tablets prescribed, plus 60 days. Persistence was deﬁned as the 
period from the ﬁrst prescription date to the date of discontinuation. A Kaplan-Meier 
survival analysis and a multivariate Cox proportional hazards regression analysis was 
performed including in the model all covarietes (demographic characteristics, comor-
bilities, previous therapies) that may potentially confound the association between 
cohort and outcome. RESULTS: The ﬁnal sample included 2382 patients (28.4% 
simvastatin; 7.3% ﬂuvastatin; 13.4% pravastatin; 30.7% atorvastatin; 20.3% rosuv-
astatin). Only 23.2% of patients persisted for 3 years of therapy. Female gender and 
absence of diabetes comorbidity were the most signiﬁcant predictors of early discon-
tinuation. CONCLUSIONS: Further studies are required to evaluate whether these 
factors are related to persistence to treatment.     
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OBJECTIVES: To describe general population self-reported EQ-5D-VAS (VAS) and 
to explore its univariate relationships with sociodemographic (SDC) and health char-
acteristics. METHODS: In 2005, the ﬁrst “Risk Factors National Survey” was under-
taken in Argentina, including 41,392 adults randomly selected from all Argentine 
provinces. Data were obtained on SDC, risk factors, and health status (EQ-5D and 
the general health question of SF-36). Mean and CI95% or median (IQR) are reported. 
All signiﬁcant differences had p values 0.01. RESULTS: VAS had a mean of 75.35 
(74.94 75.75) and a median of 80 (70–90). General population mean and median 
social TTO based weights were 0.902 (0.898–0.905) and 1 (0.88–1). The range of 
reported limitations in each of the EQ-5D domains ranged from 2.9% in self-care to 
30.9% in pain/discomfort. 44.9% had at least some limitation in one of the EQ-5D 
states, and 19.9% had a self-reported fair or poor health. VAS had a correlation of 
0,49 with TTO based social weights. General Health was strongly correlated to VAS: 
those with excellent health had a mean of 91.76, while those with poor health had a 
mean of 39.43. Subjects that reported having a health problem in the last month had 
signiﬁcantly less VAS than those who did not: 70.66 vs. 80.39. VAS was signiﬁcantly 
related to cardiovascular risks factors (high blood pressure, high-cholesterol, over-
weight, high glycemia, low physical activity) except smoking. VAS was signiﬁcantly 
lower in females, in the elderly, in subjects with less education, lower household 
income, and unemployed. CONCLUSIONS: VAS showed expected relations with 
SDC variables, with General Health, and in general, it showed to behave as expected 
with the presence of cardiovascular risk factors with the exception of smoking. This 
is one of the few general population surveys in Latin America that incorporated the 
EQ-5D tool to describe population health status.
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OBJECTIVES: The study aimed to describe common adverse events associated with 
atrial ﬁbrillation medications, as well as atrial ﬁbrillation (AF) itself. The AF and 
adverse event descriptions were used to estimate societal utility values in the UK. 
METHODS: AF base health state descriptions were produced based on EQ-5D survey 
data with input from patients and clinicians. Adverse event descriptions were bolted 
to the EQ-5D derived base AF health states so that the associated disutility of speciﬁc 
treatment adverse events could be described. The health states described both parox-
ysmal/persistent and permanent AF along with 14 adverse events. Interviews with ﬁve 
AF experienced clinicians and six AF patients were carried out to assess the content 
and face validity of the health states. In total, 127 members of the UK general public 
valued the health states in a time trade-off (TTO) interview and ranking task. 
RESULTS: The study revealed the public preferences for atrial ﬁbrillation and associ-
ated adverse event health states. There was a range of disutility reported for the 
adverse events from 0.01 for dizziness, 0.03 for rash, 0.08 for diarrhoea, 0.10 
for hypothyroidism, to 0.17 for pulmonary complications. CONCLUSIONS: The 
study provides insight into the importance of atrial ﬁbrillation treatment adverse 
events on patient’s quality of life. As atrial ﬁbrillation is a largely asymptomatic condi-
tion, the impacts of treatment adverse events on health related quality of life are 
amongst the most important factors considered in treatment decisions. The utility 
values collected in this study may prove useful in populating cost-effectiveness 
analyses.
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OBJECTIVES: Factors inﬂuencing preferences towards type of abdominal aortic aneu-
rysm (AAA) have been scarcely investigated. The objective was to identify character-
istics important for physicians, patients and their caregivers in the treatment of AAA. 
METHODS: We conducted a Discrete Choice Study involving AAA patients, their 
caregivers and experienced vascular surgeons. Participants self-completed question-
naires including 4–8 choice sets comparing pairs of options obtained from a factorial 
combination of 6 characteristics previously selected during a focus group and pilot 
study: type of anaesthesia (general vs. local); recovery time to everyday basic activities 
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(2 vs. 4 days); risk of re-intervention at 5 years (7% vs. 15%); complexity of follow-up 
(with vs. without CT examination); risk of major complications (2% vs. 5%); addi-
tional cost of intervention (a0 vs. a2000). The respondents were asked to choose the 
preferred described treatment among the options presented. The relative importance 
(RI) of each characteristic included in the scenarios was estimated by adopting a con-
ditional logistic regression model. RESULTS: 157 patients, 102 caregivers and 30 
surgeons from 9 Italian hospitals participated. Patients’ mean age  72.6 (49–88) years, 
male  91.7%. Fifty-four percent were expecting to undergo repair intervention, the 
others already received endovascular (43.4%) or surgical (50.6%) treatment. Overall, 
major complication risk was considered the most important characteristic (RI  
42.3%), then cost (RI  24.5%), risk of re-intervention at 5 years (19.2%), recovery 
time (RI  9.0%), complexity of follow-up (RI  8.7%). Type of anaesthesia was 
considered the least important characteristic (RI  3.6%). Subgroup analyses showed 
some different preferences: only patients considered signiﬁcant the recovery time and 
only physicians assigned signiﬁcant importance to the complexity of follow-up. CON-
CLUSIONS: While some characteristics (e.g. major complication rate) obtained the 
anticipated relative importance, other attributes (type of anaesthesia, follow-up, cost) 
showed different values than expected. Knowledge of preferences for AAA treatment 
options that can inﬂuence decision making and/or beneﬁts can help to optimize treat-
ment strategies.
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OBJECTIVES: Venous thromboembolism (VTE) is a common disorder. In Germany 
the current standard of thromboprophylaxis is subcutaneously administered low-
molecular-weight heparin. Meanwhile, orally administered alternatives are available. 
Primary objective of the study was to investigate patient burden and preferences and 
time consumption in the use of thromboprophylaxis. METHODS: The open, prospec-
tive observational study, enrolling adult patients after elective total hip (THR) and 
knee (TKR) replacement, was carried out from October 2008 until March 2009. Time 
was recorded for individual steps in the administration process ranging from syringe 
preparation, syringe administration, tablet preparation to tablet administration. Fur-
thermore patient-satisfaction, burden of daily subcutaneous administration and daily 
intake of tablets were recorded. Preference of patient for an oral or subcutaneous 
administration was inquired. RESULTS: The investigations were conducted in 6 
general hospitals and 6 rehab centers. 178 patients answered the questionnaire (41.4% 
TKR, 58,6% THR). The patients were on average 68.38 years old (SD: 9.82; TKR: 
69.69 years, SD: 7.31; THR: 67.22 years, SD:11.29), 73,6% (TKR: 81,9%, THR: 
67.6%) regularly (longer than 6 months) take tabletts. Most of the patients (71.9%, 
TKR: 72.2 %; THR: 70.59%) would prefer a tablet. Total time required for syringe 
preparation and administration was 73.11 sec (SD: 34.06 sec) compared to 26.98 sec 
(SD: 19.41 sec) for tablet. Most time-consuming process was syringe administration 
(50.27 sec, SD: 31.22 sec), followed by syringe preparation (22.84 sec, SD: 13.61 sec), 
tablet administration (18.17 sec, SD: 18.52) and preparation of tablet (8.82, SD: 5.79). 
CONCLUSIONS: Occasionally, only little data were available for patient preferences 
and burden of subcutaneous administration compared to oral medication. The major-
ity of patients would prefer the intake of a tablet. Also it was shown that in daily 
hospital routine a reduction of total time for thromboprophylaxis by using a tablet 
instead of a syringe is possible.
PCV139
PREFERENCE AND WILLINGNESS-TO-PAY STUDY TO ASSESS THE 
VALUE OF AN ANTICOAGULATION THERAPY MODELLED ON 
DABIGATRAN ETEXILATE USING DISCRETE CHOICE ANALYSIS: 
A UK PILOT STUDY OF ATRIAL FIBRILLATION PATIENTS  
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OBJECTIVES: To assess preferences for and valuation of attributes of anticoagulation 
therapy (ACT) modelled on the oral direct thrombin inhibitor dabigatran etexilate 
(DAB) relative to warfarin in UK atrial ﬁbrillation (AF) patients receiving warfarin. 
METHODS: The pilot study employed discrete choice analysis to derive preference 
and willingness-to-pay (WTP) estimates, based on treatment attributes that distinguish 
DAB from warfarin. Attributes included: dose frequency; anticoagulation monitoring; 
diet, alcohol and certain analgesic restrictions; use of different tablet strengths to make 
up correct daily dose. Stroke risk on therapy was assumed not to differ between DAB 
and warfarin. AF patients (n  32) currently receiving warfarin (mean time on therapy 
 45.0mo) were asked to make pair-wise medication choices between a ﬁxed scenario 
representing warfarin and 12 alternatives, including a scenario modelled on DAB, ﬁrst 
without and then with consideration of cost. Comparisons were designed to elicit 
trade-offs to determine preferences. Statistical analysis (logistic regression models) of 
preference without cost consideration excluded any irrational traders. Analysis of 
WTP excluded both irrational and non-traders. RESULTS: Rational respondents (n  
30) showed no signiﬁcant preference between an ACT modelled on DAB and warfarin 
(OR  0.95 [95%CI: 0.28–3.25]). However, respondents signiﬁcantly preferred a 
medication that avoided different tablet strengths (p  0.011), i.e., an attribute in 
favour of DAB. Rational traders (n  19) were willing to pay an incremental £26.60 
[95%CI: 66.00, 128.00] per month for DAB. A demand curve indicated that 72% 
and 50% would choose DAB over warfarin at an incremental cost of zero and £40 
respectively. CONCLUSIONS: AF respondents receiving warfarin showed indifference 
between an ACT modelled on DAB and warfarin, perhaps reﬂecting respondents’ 
familiarity and success with, and acceptance of the limitations of warfarin. Among 
respondents who were willing to trade, WTP for DAB was not signiﬁcant. This pilot 
was limited by the high proportion (41%) of non-traders in the study.
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OBJECTIVES: To assess preferences for and valuation of attributes of an anticoagula-
tion therapy (ACT) modelled on the oral direct thrombin inhibitor dabigatran etexilate 
(DAB) relative to warfarin in UK atrial ﬁbrillation (AF) patients, naïve to warfarin. 
METHODS: The pilot study employed discrete choice analysis to derive willingness-
to-pay (WTP) estimates as a measure of preference, based on treatment attributes that 
distinguish DAB from warfarin. Attributes included: dose frequency; anticoagulation 
monitoring; diet, alcohol and certain analgesic restrictions; use of different tablet 
strengths to make up correct daily dose. Stroke risk was assumed not to differ between 
DAB and warfarin. Warfarin-naïve AF patients (n  32) made pair-wise medication 
choices between a ﬁxed scenario representing warfarin and 12 alternatives, including 
a scenario modelled on DAB, ﬁrst without and then with consideration of cost. Com-
parisons were designed to elicit trade-offs to determine preferences. Statistical analysis 
(logistic regression models) of preference without cost consideration excluded any 
irrational traders. Analysis of WTP excluded both irrational and non-traders. 
RESULTS: When cost was not considered, rational respondents (n  30) showed sig-
niﬁcant preference for an ACT modelled on DAB over warfarin (OR  3.65 [95%CI: 
1.09–12.22]). Avoiding different tablet strengths was a signiﬁcant choice driver (p  
0.006). Rational traders (n  18) were willing to pay an incremental £73.90 [95%CI: 
17.30–141.40] per month for DAB. A demand curve indicated that 88.4% would 
choose DAB over warfarin at zero incremental cost and 50% would choose DAB at 
an incremental of £49. In these respondents, avoiding INR monitoring was a signiﬁ-
cant choice driver (p  0.039). CONCLUSIONS: Warfarin-naïve AF patients showed 
a strong preference for an ACT modelled on DAB over warfarin. Among respondents 
who were willing to trade, there was a signiﬁcant WTP for the convenience of DAB. 
This pilot study of WTP was limited by the high proportion (37.5%) of respondents 
who were unwilling to trade.
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OBJECTIVES: To explore upper gastrointestinal (GI) symptoms in patients with 
 cardiovascular (CV) risk who require low-dose acetylsalicylic acid (ASA; aspirin) 
therapy, and patients’ evaluation of GI symptoms. METHODS: This multicentre, 
observational study (ClinicalTrials.gov identiﬁer: NCT00681759; AstraZeneca study 
code: D961FC00004), conducted at 77 centres in USA, Canada and France, included 
patients q18 years at risk of or with CV disease, prescribed daily low-dose ASA (75–
325 mg) within the past 5 years or who were about to begin low-dose ASA therapy. 
Patients were surveyed to collect 12-months retrospective data on: GI symptoms, 
low-dose ASA use, and the impact of dyspeptic symptoms on adherence to low-dose 
ASA and other CV medications. Patients completed the 12-item Short-Form Health 
Survey (SF-12), the Hospital Anxiety and Depression Scale (HADS) and the 8-item 
Morisky Medication Adherence Scale (MMAS-8). RESULTS: In total, 1770 patients 
(mean age 57 years; 54% women) were assessed; 81.0% were aged 70 years. Most 
patients (71%) needed low-dose ASA for secondary or high-risk primary CV preven-
tion; 29% of patients were low-dose ASA-naïve. Among patients with GI symptoms 
(n  935) in the past year, 547 (58.5%) experienced GI symptoms within 14 days 
prior to survey completion. Of these, 380 (69.5%) attributed sleeping difﬁculties 
during the previous week to their GI symptoms; one quarter described sleeping 
 difﬁculties as occurring often or daily. A total of 366 patients (66.9%) had dyspeptic 
symptoms in the past 14 days. Patients who experienced dyspeptic symptoms had 
signiﬁcantly worse SF-12 domain scores (all p  0.01) and HADS anxiety and depres-
sion domain scores (p  0.01) than those without dyspeptic symptoms. Patients with 
dyspeptic symptoms taking CV medications, had signiﬁcantly lower CV medication 
compliance scores, than patients without dyspeptic symptoms (p  0.03). CONCLU-
SIONS: Among patients requiring low-dose ASA for cardioprotection, those who 
experience dyspeptic symptoms report worse health scores, increased anxiety and 
depression levels, and poorer compliance with CV medications.
